View Archive

Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Celgene Corporation and Ipsen Biopharmaceuticals, Inc.

Providing Patient-Centric Care in Pancreatic Cancer: Therapeutic Sequencing, Chemotherapy, and Novel Agents

Providing Patient-Centric Care in Pancreatic Cancer: Therapeutic Sequencing, Chemotherapy, and Novel Agents

Tuesday, July 14, 2020

Live Webcast! 8:00 PM – 9:30 PM ET


Pancreatic adenocarcinoma remains among the most challenging malignancies to treat, but recent clinical trials have expanded potential treatment options and increased the potential for improvements in patient care and outcomes. Following many years of negative studies, new drug combinations and new drug formulations for improved delivery are changing the treatment landscape for pancreatic cancer. With data emerging at a rapid pace, treating patients with pancreatic cancer will continue to become more complex as new first-line and later-line treatment options become available. In addition, numerous clinical trials are investigating promising novel agents and treatment approaches for patients with advanced pancreatic cancers. For clinicians, decision making about how best to use current and emerging treatment strategies, and which combinations can offer improved outcomes, remains a challenge.

In this live, interactive, virtual symposium, Providing Patient-Centric Care in Pancreatic Cancer: Therapeutic Sequencing, Chemotherapy, and Novel Agents, the latest cutting-edge data will be presented within a framework of tightly integrated patient cases. Experts in the management of pancreatic cancer will discuss clinical trial evidence informing guideline-based treatment approaches; placing these data sets in the context of evolving treatment standards in the field; the emerging role of maintenance therapy; differential toxicity considerations in multiple lines of care and the mitigation of adverse events; and novel therapeutic agents in clinical trials for advanced pancreatic cancer. The case-based format will encourage sharing of best practices, evolving strategies, and clinical skills. Embedded Q&A sessions with the faculty will allow participants to seek guidance on challenges they face in their own practices.

Benefits of Attending

  • Learn about the most recent clinical advances for patients with pancreatic cancer
  • Hear experts discuss emerging data in the context of treatment decision making for patients with pancreatic cancer
  • Integrate emerging and investigational therapies into treatment planning for patients with pancreatic cancer
  • Incorporate strategies to effectively identify and manage adverse events that may occur with treatments for pancreatic cancer

Acknowledgement of Commercial Support

This activity is supported by educational grants from Celgene Corporation and Ipsen Biopharmaceuticals, Inc.

Target Audience

This educational program is directed toward medical oncologists, surgical oncologists, and radiation oncologists who treat pancreatic cancer. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of patients with pancreatic cancer are also invited to attend.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Evaluate recent evidence regarding novel agents and approaches in treatment sequencing in pancreatic cancer.
  • Recommend appropriate therapeutic approaches across multiple lines of therapy for patients with advanced pancreatic cancer based on available evidence, guideline recommendations, and disease- and patient-specific characteristics.
  • Identify patients with pancreatic cancer who are candidates for experimental therapy in ongoing clinical trials.
  • Integrate mitigation and management of treatment-related toxicities into clinical scenarios for patients with pancreatic cancer.

Program Chair

Shubham Pant, MD
Shubham Pant, MD
Associate Professor, Departments of Investigational Cancer Therapeutics and Gastrointestinal Medical Oncology
Associate Director, Department of Sheikh Ahmed Center for Early Phase Drug Development of Pancreatic Cancer Research
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX


2 Ways to Register
  1. Online: click here.
  2. Phone: Please call (888) 949-0045 or (609) 378-3701.
Physicians' Education Resource®
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
Registration Fee - Free

For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.

Physicians' Education Resource®, LLC (PER®) fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us in order to receive service. Please call (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited.  This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.

By attending a PER® conference, meeting or related activity ("Events"), all participants, attendees, exhibitors, sponsors, and guests ("you") create an agreement between you and PER® regarding the use and distribution of your image, including but not limited to your name, voice, and likeness ("Image"). By attending the Events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you and you grant permission to PER® (and its agents) to utilize, in perpetuity, your Image in any electronic or print distribution, or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER®.

Meeting information is accurate at the time of posting.

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.


You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

Professional Information


Calendar of Events
Filter By